Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

CUMULATIVE SUPPLEMENT 1

AUG '83 - SEP '83



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (✖) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. SUBSCRIPTION FORM

A subscription form for the publication has been provided at the end of this supplement for use in obtaining additional subscriptions.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '83 (BASELINE)
DRUG PRODUCTS LISTED	6679
SINGLE SOURCE	1908 (28.6%)
MULTISOURCE(1)	4771 (71.4%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)
EXCEPTIONS(2)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-
NUMBER OF APPLICANTS	304

B. ACTIVITY FOR SUPPLEMENT NUMBER 1

	AUG '83	SEPT '83	CUMULATIVE
DRUG PRODUCTS ADDED:	71	61	132
NEWLY APPROVED	70	58	128
DESI EFFECTIVE	0	1	1
REMARKETED	1	2	3
DRUG PRODUCTS REMOVED:	10	26	36
WITHDRAWN APPROVAL	0	0	0
RX TO OTC SWITCH	0	2	2
DISCONTINUED MARKETING	10	24	34
NET GAIN IN DRUG PRODUCTS	61	35	96
SINGLE SOURCE PRODUCTS APPROVED	8	19	27
MULTISOURCE DRUG PRODUCTS APPROVED	63	42	105
NEW MOLECULAR ENTITIES APPROVED:	0	1	1
AS THE ENTITY	0	0	0
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	0	1	1

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (i.e., AVAILABLE FROM MORE THAN ONE APPLICANT)
(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)

AMINOPHYLLINE (PAGE 3-8)

>DLT > /LIQUID; ORAL/
>ADD > SOLUTION; ORAL
>ADD > AMINOPHYLLINE
>ADD > AA ROXANE LABORATORIES 105MG/5ML*

TABLET; ORAL
AMINOPHYLLINE
>ADD > BD BARR LABORATORIES 100MG*
>ADD > BD 200MG*

>ADD > ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-15)

>ADD > TABLET; ORAL
>ADD > ASPIRIN AND CAFFEINE W/ BUTALBITAL
>ADD > PUREPAC/KALIPHARMA 325MG;50MG;40MG*

ASPIRIN; BUTALBITAL; CAFFEINE; PHENACETIN (PAGE 3-15)

TABLET; ORAL
A.P.C. W/ BUTALBITAL
>DLT >/AA/ /PUREPAC/KALIPHARMA/ /200MG;50MG;40MG;130MG/

>ADD > ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE (PAGE 3-15)

>ADD > CAPSULE; ORAL
>ADD > SYNALGOS-DC
>ADD > IVES LABS/AMHO 356.4MG;30MG;16MG*

ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-15)

CAPSULE; ORAL
PROPOXYPHENE COMPOUND 65
>DLT >/AA/ /TOWNE PAULSEN/ /227MG;32.4MG;162MG;65MG/
>DLT > /REPRO COMPOUND 65/
>DLT >/AA/ /REID-PROVIDENT LABS//227MG;32.4MG;162MG;65MG/
>DLT > /SK-65 COMPOUND/
>DLT >/AA/ /SK&F LABORATORIES/ /227MG;32.4MG;162MG;65MG/

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
DARVON COMPOUND-65
>ADD > AA ELI LILLY INDSTRS/PR 389MG;32.4MG;65MG
>ADD > SK-65 COMPOUND
>ADD > AA SK&F LABORATORIES 389MG;32.4MG;65MG*

>ADD > ASPIRIN; CARISOPRODOL (PAGE 3-16)

>ADD > TABLET; ORAL
>ADD > SOMA COMPOUND
>ADD > WALLACE PHARMS/C-W 325MG;200MG*

>ADD > ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE (PAGE 3-16)

>ADD > TABLET; ORAL
>ADD > SOMA COMPOUND W/ CODEINE
>ADD > WALLACE PHARMS/C-W 325MG;200MG;16MG*

>ADD > ASPIRIN; HYDROCODONE BITARTRATE (PAGE 3-16)

>ADD > TABLET; ORAL
>ADD > VICOPRIN
>ADD > KNOLL PHARMACEUTICAL 500MG;5MG*

BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
SPECTROBID
>ADD > PFIZER LABS/PFIZER 800MG*

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL
>ADD > BETAMETHASONE VALERATE
>ADD > AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
>ADD > AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
>ADD > BETATREX
>ADD > AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*

LOTION; TOPICAL
>ADD > BETAMETHASONE VALERATE
>ADD > AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
>ADD > AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
>ADD > BETATREX
>ADD > AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*
VALISONE
>ADD > AB SCHERING EQ 0.1% BASE

OINTMENT; TOPICAL
>ADD > BETAMETHASONE VALERATE
>ADD > AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
>ADD > AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
>ADD > BETATREX
>ADD > AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*
VALISONE
>ADD > AB SCHERING EQ 0.1% BASE

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION
MARCAINE HCL W/ EPINEPHRINE
> ADD > AP BREON LABS/STERLING 0.5%;0.0091MG/ML
> ADD > AP 0.75%;0.0091MG/ML
> ADD > SENSORCAINE
> ADD > AP ASTRA HOSP PHARM 0.5%;0.0091MG/ML*
> ADD > AP 0.75%;0.0091MG/ML*

> DLT > /CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE; PHENACETIN/
(PAGE 3-24)

> DLT > /TABLET; ORAL/
> DLT > /SOMA COMPOUND W/ CODEINE/
> DLT > /WALLACE PHARMS/C-W/ /32MG;200MG;16MG;160MG/

CAFFEINE; CARISOPRODOL; PHENACETIN (PAGE 3-25)

TABLET; ORAL
> DLT > /SOMA COMPOUND/
> DLT >/AB/ /WALLACE PHARMS/C-W/ /32MG;200MG;160MG/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
> ADD > DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER
> ADD > AM MCGAW/AM HOSP 510MG/100ML;30GM/100ML;
> ADD > 200MG/100ML;9.2GM/100ML;
> ADD > 9.6GM/100ML*
> ADD > 510MG/100ML;30GM/100ML;
> ADD > 200MG/100ML;9.4GM/100ML;
> ADD > 11GM/100ML*
> ADD > DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER
> ADD > AM MCGAW/AM HOSP 510MG/100ML;50GM/100ML
> ADD > 200MG/100ML;9.2GM/100ML;
> ADD > 9.6GM/100ML*
> ADD > 510MG/100ML;50GM/100ML;
> ADD > 200MG/100ML;9.4GM/100ML;
> ADD > 11GM/100ML*

> ADD > CEFTIZOXIME SODIUM (PAGE 3-30)

> ADD > INJECTABLE; INJECTION
> ADD > CEFIZOX
> ADD > SK&F LABORATORIES EQ 1GM BASE/VIAL*
> ADD > EQ 2GM BASE/VIAL*

CHLORDIAZEPOXIDE (PAGE 3-33)

> ADD > CAPSULE, CONTROLLED RELEASE; ORAL
> ADD > LIBRELEASE
> ADD > HOFFMANN-LA ROCHE 30MG*

CHLOROTHIAZIDE (PAGE 3-35)

TABLET; ORAL
CHLOROTHIAZIDE
> ADD > AB CHELSEA LABORATORIES 250MG*
> ADD > AB 500MG*

CHLORPHENIRAMINE MALEATE (PAGE 3-36)

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
> DLT >/AA/ /JOHNE PAULSEN/ /4MG/

CHLORTHALIDONE (PAGE 3-38)

TABLET; ORAL
CHLORTHALIDONE
> ADD > AB PUREPAC/KALIPHARMA 50MG*

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL
CHLORZOXAZONE
> ADD > AA PAR PHARMACEUTICAL 250MG*

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
REDISOL
> DLT >/AP/ MS&D/MERCK /0.1MG/ML/
SYTOBEX
> DLT >/AP/ PARKE DAVIS/W-L /0.1MG/ML/

DESOXIMETASONE (PAGE 3-49)

> ADD > OINTMENT; TOPICAL
> ADD > TOPICORT
> ADD > HOECHST-ROUSSEL 0.25%*

DEXAMETHASONE (PAGE 3-49)

>ADD>		SOLUTION; ORAL		
>ADD>		DEXAMETHASONE		
>ADD>		ROXANE LABORATORIES	0.5MG/5ML¤	
>ADD>		DEXAMETHASONE INTENSOL		
>ADD>		ROXANE LABORATORIES	0.5MG/0.5ML¤	
		TABLET; ORAL		
		DECADRON		
>ADD>	BP	MS&D/MERCK	6MG	
		DEXAMETHASONE		
>ADD>	BP	ROXANE LABORATORIES	6MG¤	
>ADD>			1MG¤	

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-50)

		INJECTABLE; INJECTION		
>DLT>		/HEXADROL PHOSPHATE/		
		HEXADROL		
>ADD>	AP	ORGANON/AKZONA	EQ 4MG PHOSPHATE/ML	
>ADD>			EQ 20MG PHOSPHATE/ML	

DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)

		INJECTABLE; INJECTION		
>DLT>		/DOPAMINE HCL IN DEXTROSE 5%/		
>ADD>		DOPAMINE HCL		
>ADD>	AP	ABBOTT LABORATORIES	5GM/100ML;80MG/100ML	
>ADD>	AP		5GM/100ML;160MG/100ML	
>ADD>		DOPAMINE HCL IN PLASTIC CONTAINER		
>ADD>	AP	ABBOTT LABORATORIES	5GM/100ML;80MG/500ML¤	
>ADD>	AP		5GM/100ML;160MG/100ML¤	
>ADD>			5GM/100ML;320MG/100ML¤	

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

		TABLET; ORAL		
		DIETHYLPROPION HCL		
>ADD>	AA	CAMALL	25MG¤	

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

		CAPSULE; ORAL		
		SK-DIPHENHYDRAMINE		
>DLT>/AA/		SK&F LABORATORIES	/25MG/	
		ELIXIR; ORAL		
>DLT>		/SK-DIPHENHYDRAMINE/		
>DLT>/AA/		/SK&F LABORATORIES/	/12.5MG/5ML/	

DISULFIRAM (PAGE 3-63)

		TABLET; ORAL		
		DISULFIRAM		
>ADD>	BX	CHELSEA LABORATORIES	250MG¤	
>ADD>	BX		500MG¤	

DOXYCYCLINE HYCLATE (PAGE 3-64)

		CAPSULE; ORAL		
		DOXYCYCLINE HYCLATE		
>ADD>	AB	CHELSEA LABORATORIES	EQ 50MG BASE	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

		INJECTABLE; INJECTION		
>ADD>		LIDOCATON		
>ADD>	AP	PHARMATON/SZ	0.01MG/ML;2%¤	
>ADD>	AP		0.02MG/ML;2%¤	

ERYTHROMYCIN (PAGE 3-67)

		OINTMENT; OPHTHALMIC		
>ADD>		ERYTHROMYCIN		
>ADD>	AT	E FOUGERA/BYK-GLDN	5MG/GM¤	
>ADD>	AT	PHARMADERM/BYK-GLDN	5MG/GM¤	
		ILOTYCIN		
>ADD>	AT	DISTA PRODS/LILLY	5MG/GM	

GENTAMICIN SULFATE (PAGE 3-79)

		CREAM; TOPICAL		
>ADD>		GENTAFAIR		
>ADD>	AT	PHARMAFAIR	EQ 1MG BASE/GM¤	
>ADD>		GENTAMICIN SULFATE		
>ADD>	AT	NMC LABORATORIES	EQ 1MG BASE/GM¤	
		INJECTABLE; INJECTION		
		GENTAMICIN SULFATE		
>ADD>	AP	ABBOTT LABORATORIES	EQ 60MG BASE/100ML¤	
>ADD>	AP		EQ 70MG BASE/100ML¤	
>ADD>	AP		EQ 80MG BASE/100ML¤	
>ADD>	AP		EQ 90MG BASE/100ML¤	
>ADD>	AP		EQ 100MG BASE/100ML¤	
>ADD>	AP		EQ 1.2MG BASE/ML¤	
>ADD>	AP		EQ 1.4MG BASE/ML¤	
>ADD>	AP		EQ 1.6MG BASE/ML¤	
>ADD>	AP		EQ 1.8MG BASE/ML¤	
>ADD>	AP		EQ 2MG BASE/ML¤	
>ADD>	AP		EQ 10MG BASE/ML¤	
>ADD>	AP		EQ 40MG BASE/ML¤	
>ADD>	AP	LYPHO-MED	EQ 40MG BASE/ML¤	

GENTAMICIN SULFATE (PAGE 3-79)

INJECTABLE; INJECTION

> ADD >		GENTAMICIN SULFATE IN PLASTIC CONTAINER	
> ADD >	AP	ABBOTT LABORATORIES	EQ 60MG BASE/100ML¤
> ADD >	AP		EQ 70MG BASE/100ML¤
> ADD >	AP		EQ 80MG BASE/100ML¤
> ADD >	AP		EQ 90MG BASE/100ML¤
> ADD >	AP		EQ 100MG BASE/100ML¤
> ADD >	AP		EQ 1.2MG BASE/ML¤
> ADD >	AP		EQ 1.4MG BASE/ML¤
> ADD >	AP		EQ 1.6MG BASE/ML¤
> ADD >	AP		EQ 1.8MG BASE/ML¤
> ADD >	AP		EQ 2MG BASE/ML¤
		ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER	
> ADD >	AP	TRAVENOL LABS	EQ 0.8MG BASE/ML¤
> ADD >	AP		EQ 80MG BASE/100ML¤

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION

> DLT >		/ANTUITRIN S/	
> DLT >/	AP/	/PARKE-DAVIS/W-L/	/5,000 UNITS/VIAL/

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL

		HOMAPIN-10	
> DLT >/	AA/	MISSION PHARMACAL	10MG
> DLT >		/SEUS-TENS SE/	
> DLT >/	AA/	/LEMMON/	/10MG/

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

TABLET; ORAL

		HYDRALAZINE HCL	
> ADD >	AA	PAR PHARMACEUTICAL	100MG¤
> ADD >	AA	PUREPAC/KALIPHARMA	50MG¤

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE (PAGE 3-89)

TABLET; ORAL

		SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	
> ADD >	AB	PUREPAC/KALIPHARMA	25MG;25MG¤

HYDROCORTISONE (PAGE 3-90)

CREAM; TOPICAL

		HYDROCORTISONE	
> ADD >	AT	BAY LABORATORIES	1%¤
> ADD >	AT		2.5%¤

HYDROCORTISONE (PAGE 3-90)

LOTION; TOPICAL

> DLT >		/DELACORT/	
> DLT >/	AT/	/MERICON INDUSTRIES/	/0.5%/
		HYDROCORTISONE	
> ADD >	AT	MERICON INDUSTRIES	0.5%
> DLT >/	AT/	/TOWNE PAULSEN/	/0.5%/

OINTMENT; TOPICAL

		HYDROCORTISONE	
> ADD >	AT	BAY LABORATORIES	1%¤
> ADD >	AT		2.5%¤

> DLT >		/SOLUTION/DROPS; OPHTHALMIC/	
> DLT >		/OPTEF/	
> DLT >		/UPJOHN/	/0.2%/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-92)

SOLUTION/DROPS; OTIC

> ADD >		NEO-OTOSOL-HC	
> ADD >	AT	CARTER-GLOGAU LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML¤

HYDROCORTISONE ACETATE (PAGE 3-93)

CREAM; TOPICAL

		HYDROCORTISONE ACETATE	
> DLT >/	AT/	/TOWNE PAULSEN/	/1%/

LOTION; TOPICAL

		DRICORT	
> DLT >/	AT/	INGRAM PHARM	0.5%
> DLT >		/HYDROCORTISONE ACETATE/	
> DLT >/	AT/	/TOWNE PAULSEN/	/0.5%/

> DLT >		/SUSPENSION/DROPS; OPHTHALMIC; OTIC/	
> DLT >		/HYDROCORTONE/	
> DLT >		/MSD/MERCK/	/1.5%/

HYDROCORTISONE VALERATE (PAGE 3-95)

OINTMENT; TOPICAL

> ADD >		WESTCORT	
> ADD >		WESTWOOD PHARMS	0.2%¤

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL

		HYDROXYZINE HCL	
> ADD >	AB	DANBURY PHARMACAL	10MG¤
> ADD >	AB		25MG¤
> ADD >	AB		50MG¤

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL
HYDROXYZINE PAMOATE
> ADD > AB VANGARD LABS/MWM EQ 25MG HCL*
> ADD > AB EQ 50MG HCL*

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
> DLT > /ANTIPRESS/
> DLT > /BP/ /LEMMON/ /25MG/
> DLT > /IMAVATE/
> DLT > /AB/ /AH ROBINS/ /25MG/
> DLT > /AB/ /50MG/

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION
ISOETHARINE HCL
> ADD > AN INTL MEDICATION SYS 0.167%
> ADD > AN ROXANE LABORATORIES 0.167%*
> ADD > AN TRAVENOL LABS 0.25%*

KANAMYCIN SULFATE (PAGE 3-102)

INJECTABLE; INJECTION
> ADD > KANAMYCIN SULFATE
> ADD > AP INTL MEDICATION SYS EQ 500MG BASE/2ML*
> ADD > AP EQ 1GM BASE/3ML*
KANTREX
> DLT > /AP/ /BRISTOL LABS/B-M/ /75MG/2ML/
> DLT > /AP/ /500MG/2ML/
> DLT > /AP/ /1GM/3ML/
> ADD > AP BRISTOL LABS/B-M EQ 75MG BASE/2ML
> ADD > AP EQ 500MG BASE/2ML
> ADD > AP EQ 1GM BASE/3ML

LIDOCAINE HYDROCHLORIDE (PAGE 3-104)

INJECTABLE; INJECTION
> ADD > LIDOCATON
> ADD > AP PHARMATON/SZ 2%*

METHYLTESTOSTERONE (PAGE 3-121)

TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE
> DLT > /BP/ /TOWNE PAULSEN/ /10MG/

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION
> ADD > METRO I.V. IN PLASTIC CONTAINER
> ADD > AP AM MCGAW/AM HOSP 500MG/100ML*

TABLET; ORAL
METRONIDAZOLE
> ADD > AB PAR PHARMACEUTICAL 250MG*
> ADD > AB 500MG*

> ADD > NANDROLONE DECANOATE (PAGE 3-125)

> ADD > INJECTABLE; INJECTION
> ADD > NANDROLONE DECANOATE
> ADD > MAURRY BIOLOGICAL 100MG/ML*

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
> ADD > NITRONAL
> ADD > AP G POHL-BOSKAMP 5MG/ML*
> ADD > 1MG/ML*
TRIDIL
> ADD > AM CRITICAL CARE/AHS 0.5MG/ML*

OXTRIPHYLLINE (PAGE 3-131)

TABLET, ENTERIC COATED; ORAL
CHOLEDYL
> ADD > AB PARKE-DAVIS/W-L 100MG
> ADD > AB 200MG
> ADD > OXTRIPHYLLINE
> ADD > AB BOLAR PHARMACEUTICAL 100MG*
> ADD > AB 200MG*

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL
> DLT > /OXLOPAR/
> DLT > /AB/ /PARKE-DAVIS/W-L/ /EQ 250MG BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL
> DLT > /UTICILLIN VK/
> DLT > /AA/ /UPJOHN/ /EQ 125MG BASE/5ML/
> DLT > /AA/ /EQ 250MG BASE/5ML/

PHENDIMETRAZINE TARTRATE (PAGE 3-138)

TABLET; ORAL
PHENDIMETRAZINE TARTRATE
>_ADD_> AA FERNDALE LABS 35MG*

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL
ADIPEX-P
>_ADD_> LEMMON 37.5MG*

POTASSIUM CHLORIDE (PAGE 3-143)

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
>_DLT_>/AP/ /TRAVENOL LABS/ /1MEQ/ML/
>_DLT_>/AP/ /3MEQ/ML/
>_DLT_>/AP/ /4MEQ/ML/

PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-147)

SOLUTION/DROPS; OPHTHALMIC
>_DLT_> /HYDELTRASOL/
>_DLT_>/AT/ /MSD/MERCK/ /EQ 0.5% PHOSPHATE/
METRETON
>_DLT_>/AT/ SCHERING EQ 0.5% PHOSPHATE

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE; ORAL
PROCAN
>_DLT_>/AB/ PARKE-DAVIS/W-L /250MG/
>_DLT_>/AB/ /500MG/

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE; ORAL
PROPOXYPHENE HCL
>_ADD_> AA RICHLYN LABORATORIES 65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET; ORAL
PROPYLTHIOURACIL
>_DLT_> /BD/ /MYLAN PHARMS/ /50MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

SYRUP; ORAL
PSEUDODINE
>_DLT_>/AA/ BAY LABORATORIES 30MG/5ML;1.25MG/5ML
>_DLT_> /TRIACIN/
>_DLT_>/AA/ /NATL PHARM MFG/BARRE/ 30MG/5ML;1.25MG/5ML/

TABLET; ORAL
>_DLT_> /TRIDODRINE/
>_DLT_>/AA/ /DANBURY PHARMACAL/ /60MG;2.5MG/
>_ADD_> TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
>_ADD_> AA CHELSEA LABORATORIES 60MG;2.5MG*

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
>_ADD_> AB VITARINE/WEST CHEM 300MG*

SELENIUM SULFIDE (PAGE 3-161)

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
>_ADD_> AT BAY LABORATORIES 2.5%*

SILVER SULFADIAZINE (PAGE 3-161)

CREAM; TOPICAL
>_DLT_> /SILVER SULFADIAZINE/
>_ADD_> SSD

>_DLT_> /SITOSTEROL;ALPHA/(PAGE 3-161)

>_DLT_> /SUSPENSION;ORAL/
>_DLT_> /CYTELLIN/
>_DLT_> /ELI LILLY/ /36MU/15ML/

SOMATROPIN (PAGE 3-165)

INJECTABLE; INJECTION
>_ADD_> ASELLACRIN 2
>_ADD_> SERONO LABS 2 IU/VIAL*
>_DLT_> /ASELLACRIN/
>_ADD_> ASELLACRIN 10

SPIRONOLACTONE (PAGE 3-166)

TABLET; ORAL
SPIRONOLACTONE
>ADD > AB PUREPAC/KALIPHARMA 25MG*

TESTOSTERONE (PAGE 3-173)

INJECTABLE; INJECTION
TESTOSTERONE
>ADD > CARTER-GLOGAU LABS 50MG/ML*

TETRACYCLINE HYDROCHLORIDE (PAGE 3-174)

TABLET; ORAL
PANMYCIN
>DLT >/AB/ UPJOHN /250MG/
SUMYCIN
>DLT >/AB/ ER SQUIBB AND SONS 250MG

THEOPHYLLINE (PAGE 3-176)

CAPSULE, CONTROLLED RELEASE; ORAL
SOMOPHYLLIN-CRT
>ADD > BC FISONS 100MG
>ADD > THEO-24
>ADD > BC SEARLE/SEARLE PHARMS 100MG*
>ADD > 200MG*
>ADD > 300MG*

SOLUTION; ORAL
THEOLAIR
>ADD > AA RIKER LABS/3M 80MG/15ML
>ADD > THEOPHYLLINE
>ADD > AA ROXANE LABORATORIES 80MG/15ML*

TABLET, CONTROLLED RELEASE; ORAL
THEOCONTIN
>ADD > BC PURDUE FREDERICK 200MG*
THEO-DUR
>ADD > BC KEY PHARMACEUTICALS 200MG

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL
THIORIDAZINE HCL
>ADD > AA NATL PHARM MFG/BARRE 100MG/ML*

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

TABLET; ORAL
MELLARIL
>ADD > AB SANDOZ PHARMS/SANDOZ 100MG
THIORIDAZINE HCL
>ADD > AB BOLAR PHARMACEUTICAL 10MG*
>ADD > AB 100MG*
>ADD > AB CORD LABORATORIES 10MG*
>ADD > AB 15MG*
>ADD > AB 25MG*
>ADD > AB 50MG*

TIMOLOL MALEATE (PAGE 3-179)

TABLET; ORAL
BLOCADREN
>ADD > MS&D/MERCK 5MG

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
>ADD > AT BAY LABORATORIES 0.025%*
>ADD > AT 0.1%*
>ADD > AT 0.5%*

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE
>ADD > AT BAY LABORATORIES 0.025%*
>ADD > AT 0.1%*
>ADD > AT 0.5%*

TRISULFAPYRIMIDINES (PAGE 3-185)

SUSPENSION; ORAL
>DLT > /TRISEM/
>DLT >/AB/ /BEECHAM LABS/BEECHAM/500MG/5ML/
>DLT > /TRISUREID/
>DLT >/AB/ /REID-PROVIDENT LABS//500MG/5ML/

TABLET; ORAL
>DLT > /TRIPLE SULFA #2/
>DLT >/AB/ /ZENITH LABORATORIES//500MG/

TROPICAMIDE (PAGE 3-186)

SOLUTION/DROPS; OPHTHALMIC
>ADD > MYDRIAFAIR
>ADD > AT PHARMAFAIR 0.5%*
>ADD > AT 1%*

>DLT > /TYBAMATE/(PAGE 3-186)

>DLT > /CAPSULE; ORAL/
>DLT > /TYBATRAN/
>DLT > /AH. ROBINS/ /25MG/
>DLT > /35MG/

VITAMIN A PALMITATE (PAGE 3-188)

CAPSULE; ORAL
>DLT > /SOLVISYN A/
>DLT >/AA/ /TONNE PAULSEN/ /EQ 50,000 UNITS BASE/

>_DLT_> /CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE; ISOPROPAMIDE/
>_DLT_> /IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE/(PAGE AD3)

>_DLT_> /CAPSULE, CONTROLLED RELEASE, ORAL/
>_DLT_> /TUSS-ORNADE/
>_DLT_> /SK&F LABORATORIES/ /20MG;8MG;2.5MG;50MG/

>_DLT_> /SOLUTION; ORAL/
>_DLT_> /TUSS-ORNADE/
>_DLT_> /SK&F LABORATORIES/ /5MG/5ML;2MG/5ML;0.75/5ML;15MG/5ML/

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL
DIPYRIDAMOLE
>_ADD_> ASCOT HOSP PHARMS 50MG

CURRENT STATUS - INEFFECTIVE

>DLT > /CARBRITAL/ /PARKE-DAVIS/W-L/
>DLT > /CARBROMAL; PENTOBARBITAL SODIUM/

>DLT > CISTIN RA'/ MCNEIL PHARM'/
>DLT > /CARBINOXAMINE MALEATE/

>DLT > /FORHISTAL/ /CIBA/CIBA-GEIGY/
>DLT > /DIMETHINDENE MALEATE/

>ADD > TUSS-ORNADE SK&F LABORATORIES
>ADD > CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE;
>ADD > ISOPROPAMIDE IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

* U.S. GOVERNMENT PRINTING OFFICE: 1983-421-927:203

SUBSCRIPTION FORM

APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
4TH EDITION (1983)

MAIL TO:

DATE:

Superintendent of Documents
Government Printing Office
Washington, DC 20402
(202) 783-3238

PURCHASER:

SHIP TO:
(If different than purchaser)

CONTACT:	TELEPHONE (Include Area Code)

METHOD OF PAYMENT

[ ] Charge my GPO Account No. _____
[ ] Purchase Order Number _____
[ ] Check enclosed for $_____
(Make check payable to Superintendent of Documents)

AUTHORIZING SIGNATURE	DATE:

DESCRIPTION	QUANTITY	UNIT PRICE	TOTAL PRICE
The 4th Edition will be published in October, 1983. Subscription includes the Approved Prescription Drug Products List and monthly Cumulative Supplements. DOMESTIC		@ $67.00	$
FOREIGN		@ $83.75	$
ENTER TOTAL			$